Epidermal Growth Factor Receptor Mutation-Positive Non–Small-Cell Lung Cancer in the Real-World Setting in Central Europe. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Ramlau, Rodryg; Cufer, Tanja; Berzinec, Peter; Dziadziuszko, Rafal; Olszewski, Włodzimierz; Popper, Helmut; Bajcic, Paolo; Dušek, Ladislav; Zbozinkova, Zuzana; Pirker, Robert
• Is Part Of: Journal of thoracic oncology. Volume 10:Issue 9(2015)
• Publication Date: 2015-09
• Subjects: Chest -- Cancer -- Periodicals; Thoracic Neoplasms -- Periodicals; 616.99494005
• DOI: 10.1097/JTO.0000000000000621
• Languages: English
• ISSNs: 1556-0864

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>The <bold>I</bold>mplementatio<bold>N</bold> of per<bold>S</bold>onalized medicine <bold>I</bold>n NSCLC in Central Europe: E<bold>G</bold>FR testing, <bold>H</bold>istopathology, and clinical fea<bold>T</bold>ures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non–small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.</p> </sec> </abstract>